COVID-19: Omicron Variant Vaccine Trial Launched by Pfizer and BionNTech
-
Pfizer and BioNTech are set to begin the clinical trial that will evaluate the safety and efficacy of the Omicron variant vaccine
-
Up to 1,420 participants between the ages of 18 and 55 will be evaluated in the trial
-
Pfizer CEO Albert Bourla has disclosed that the vaccine to tackle the Omicron variant will be ready by March
Pfizer and BioNTech announce on Tuesday that a clinical trial had begun to evaluate the safety and effectiveness of the COVID-19 Omicron variant vaccine. The vaccine was developed following concerns that the current crop of vaccines is not effective at preventing infections and illness caused by the Omicron variant.
According to CNBC, Pfizer CEO Abert Bourla had earlier revealed that the vaccine will be available by March. The Pfizer boss also revealed that the vaccine will be effective against other COVID variants that are circulating.
BioNTech CEO Ugur Sahin also warned that recent data have indicated that the current vaccine is showing less efficacy against mild illnesses from the Omicron compared to previous strains of COVID-19. In his statement that was released on Tuesday, Sahin claimed that the company’s goal is to create a vaccine that endures and provides protection against Omicron.
Read also: Needle-free COVID 19 Vaccine Tested in the UK
The clinical study for the Omicron variant vaccine will evaluate up to 1,420 people between the ages of 18 and 55.
While Bourla claims that he isn’t sure if an Omicron-specific vaccine is required right now or how it will be used, he stated that a lot of countries have been requesting it, so Pfizer will make it available.
Follow Naija.fm on our social media handles Facebook, Instagram, and Twitter to keep up with trending news, breaking news, entertainment news, and hot gist.
